曲唑匹罗在胃轻瘫患者中的安全性、药代动力学与药效学研究
这项2a期试验纳入51例胃轻瘫患者,评估每日两次曲唑匹罗(5、25、100 mg)的安全性、药代动力学与药效学。曲唑匹罗耐受良好,无心血管或中枢神经系统不良事件,半衰期4-5小时,25 mg时血清催乳素升高提示靶点结合;各剂量及甲氧氯普胺均未显著影响胃排空,但25 mg组在容积至饱腹感方面优于安慰剂(88.5 vs -26.3 mL;P=0.019)。
要点
- 曲唑匹罗耐受良好,未观察到心血管或中枢神经系统不良事件。
- 所有剂量快速吸收和消除,半衰期4-5小时,25 mg时催乳素升高提示D2/D3受体结合。
- 曲唑匹罗和甲氧氯普胺均未显著影响胃排空,但25 mg组容积至饱腹感优于安慰剂。
核心结论
- 曲唑匹罗耐受良好且安全性良好,支持其用于胃轻瘫的进一步开发。
研究设计与样本
- 2a期试点研究,纳入51例胃轻瘫参与者,评估每日两次曲唑匹罗5、25和100 mg,以甲氧氯普胺为内部对照。
主要发现
- 曲唑匹罗耐受良好,无心血管或中枢神经系统不良事件。
- 所有曲唑匹罗剂量快速吸收和消除,t1/2z为4-5小时。
- 血清催乳素升高证实D2/D3受体靶点结合,在曲唑匹罗25 mg时达峰。
- 曲唑匹罗或甲氧氯普胺均未显示对胃排空的影响(P > 0.05)。
- 曲唑匹罗25 mg组容积至饱腹感为88.5 mL,安慰剂组为-26.3 mL(P = 0.019)。
关键数值与推荐
- 曲唑匹罗25 mg组与安慰剂组容积至饱腹感分别为88.5 mL和-26.3 mL(P = 0.019)。
- 曲唑匹罗25 mg组与安慰剂组总体症状评分改善无统计学显著性(P = 0.182)。
- 曲唑匹罗或甲氧氯普胺对胃排空无显著影响(P > 0.05)。
临床怎么用
- 曲唑匹罗可能为胃轻瘫提供耐受性良好的治疗选择,但需进一步研究确认疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gastroparesis is a chronic gastric motility disorder. Dopamine D2 /D3 receptor antagonists metoclopramide and domperidone are current treatment options but are associated with central nervous system and cardiovascular safety concerns, respectively, precluding chronic use. Trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, is under development for chronic treatment of moderate-to-severe gastroparesis. Nonclinical data suggest trazpiroben will have D2 /D3 receptor antagonism comparable with metoclopramide or domperidone. AIMS: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics (effect on prolactin and gastric function) of twice-daily trazpiroben (5, 25 and 100 mg) in participants with gastroparesis. METHODS: This phase 2a pilot study evaluated gastric emptying using the gastric emptying breath test, with metoclopramide as an internal control. Gastric accommodation and gastroparesis symptoms were assessed using the nutrient drink test and American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index-Daily Diary, respectively. RESULTS: Overall, 51 participants were enrolled. Trazpiroben was well tolerated, demonstrating a favourable safety profile without cardiovascular or central nervous system adverse events. All trazpiroben doses were rapidly absorbed and eliminated (t1/2z 4-5 hours), and D2 /D3 receptor target engagement confirmed by increased serum prolactin (peaking at trazpiroben 25 mg). No effect on gastric emptying was demonstrated with trazpiroben or metoclopramide (P > 0.05), although benefits in volume-to-fullness were seen at trazpiroben 5 mg (P > 0.05) and 25 mg (88.5 vs -26.3 mL; P = 0.019), and nonsignificant numerical aggregate symptom score improvements were observed with trazpiroben 25 mg vs placebo (P = 0.182). CONCLUSIONS: Trazpiroben was well tolerated with a favourable safety profile, supporting its further development for the treatment of gastroparesis. ClinicalTrials.gov identifier: NCT03268941.
引用
- Kuo B, Scimia C, Dukes G, et al. Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis. Aliment Pharmacol Ther. 2021. PMID: 34148244. doi:10.1111/apt.16451
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。